Coverage
-
October 31, 2022
Eli Lilly & Co. ran into tough questions about the Seventh Circuit's power to review a closely watched case over the scope of a multibillion-dollar drug discount program, after a judge asked Monday if a violation letter was something the court could look at now.
1 other articles on this case.
View all »